Caris Life Sciences, Inc. (CAI) Balance Sheet
As of 2026-06-30 (10-Q), Caris Life Sciences, Inc. (CAI) reported total assets of $1.2B, total liabilities of $637.9M and shareholders' equity of $591.7M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $692.7M. Long-term debt: $393.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CAICaris Life Sciences, Inc.Follow CAI — free
—
Price chart with a free account
- Market cap
- 9.0B
- P/E TTM
- 85.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|
| Cash and equivalents | 0.80 | 0.69 | |
| Short-term investments | 0.00 | 0.10 | |
| Receivables | 0.11 | 0.12 | |
| Current assets | 1.00 | 1.06 | |
| Total assets | 1.13 | 1.23 | |
| Current liabilities | 0.13 | 0.19 | |
| Long-term debt | 0.38 | 0.39 | |
| Short-term debt | 0.00 | 0.00 | |
| Total liabilities | 0.55 | 0.64 | |
| Shareholders' equity | 0.58 | 0.59 |
USD billions · SEC XBRL
Caris Life Sciences, Inc. — questions
- How much cash does Caris Life Sciences, Inc. have?
- $692.7M in cash and cash equivalents as of 2026-06-30.
- How much debt does Caris Life Sciences, Inc. have?
- $393.0M of long-term debt and $178000 due within a year as of 2026-06-30.
- What are Caris Life Sciences, Inc.'s total assets?
- $1.2B as of 2026-06-30.
- What is Caris Life Sciences, Inc.'s shareholders' equity?
- $591.7M as of 2026-06-30.
Every figure on this page comes from Caris Life Sciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.